SEC Form 4 · accession 0001179110-17-002952

ABBOTT LABORATORIES · ABT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Executive Vice President

Period of report

Feb 17, 2017

Accepted (ET)

Feb 22, 2017 · 5:57 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000001800

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common shares without par value^F1	Feb 17, 2017	A	14,273	$0.00	A	288,797	D
Common shares without par value	Feb 21, 2017	M	93,400	$26.6973	A	382,197	D
Common shares without par value	Feb 21, 2017	S	93,400	$45.00	D	288,797	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F2	$44.40	Feb 17, 2017	A	98,714	A	Feb 17, 2018	Feb 16, 2027	Common shares	98,714	98,714	D
Option (right to buy)^F3	$26.6973	Feb 21, 2017	M	93,400	A	Feb 8, 2011	Feb 14, 2018	Common shares	93,400	0	D

F1These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,905 on 2/17/2018, 32,904 on 2/17/2019, and 32,905 on 2/17/2020.
F3Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).